Results 41 to 50 of about 16,215 (185)

Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma

Neoplasia: An International Journal for Oncology Research, 2016
BACKGROUND & AIM: Aflibercept known as ziv-aflibercept in the United States is a soluble decoy receptor of both vascular endothelial growth factor (VEGF) receptor-1 and -2 known to inhibit the binding of VEGF and placental growth factor (PlGF) to VEGF ...
Takuji Torimura, Hideki Iwamoto, Toru Nakamura, Mitsuhiko Abe, Yu Ikezono, Fumitaka Wada, Takahiko Sakaue, Hiroshi Masuda, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano   +11 more
doaj   +1 more source

Impact of delayed appointments on treatment outcomes in neovascular macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola, Pekko Hujanen, Hannu Uusitalo, Hannele Uusitalo‐Järvinen   +3 more
wiley   +1 more source

Visual acuity is reduced with increasing central retinal thickness, but also with higher age and female sex in diabetic macular oedema

Acta Ophthalmologica, EarlyView.
Abstract Introduction The increasing number of patients with diabetes has increased the incidence of diabetic macular oedema (DME) with the accompanying risk of developing visual loss. The purpose of the present study was to describe the contributions of increased central retinal thickness (CRT) and other risk factors to the reduction in visual acuity ...
Signe Krejberg Jeppesen, Toke Bek
wiley   +1 more source

Neovascular glaucoma at a tertiary Centre in Finland, 2008–2024: A retrospective cohort study

Acta Ophthalmologica, EarlyView.
Abstract Purpose Neovascular glaucoma (NVG) is a refractory secondary glaucoma, yet longitudinal outcome data remain limited. This study reports its aetiologies, treatments and outcomes. Methods Patients with NVG were identified through electronic medical record review.
Gilbert Simons, Mikael von Fersen, Paula Summanen, Mika Harju   +3 more
wiley   +1 more source

Predictors of visual acuity, intraocular pressure and pain in neovascular glaucoma

Acta Ophthalmologica, EarlyView.
Abstract Purpose To identify factors associated with best‐corrected visual acuity (BCVA), intraocular pressure (IOP) and ocular pain in neovascular glaucoma (NVG). Methods The retrospective cohort included all patients diagnosed with NVG during 2008–2024 at Helsinki University Hospital, Finland. Linear mixed‐effects models used pre‐specified covariates,
Gilbert Simons, Mikael von Fersen, Alexandra Dahlberg, Ville Vartiainen, Paula Summanen, Mika Harju   +5 more
wiley   +1 more source

THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA [PDF]

, 2022
Compare the 3-year outcomes of ranibizumab versus aflibercept in eyes with diabetic macular edema in daily practice. METHODS: This was a retrospective analysis of naive diabetic macular edema eyes starting intravitreal injections of ranibizumab (0.5 mg ...
Arnold, Jennifer,, Mónica Asencio Duran, Creuzot-Garcher, Catherine, Francesco Viola, Daniel Barthelmes, Duran, Mónica, Asencio, Duran, Mónica,, Gabrielle, Pierre-Henry, David Squirrell, Gillies, Mark, Mehta, Hemal, Arnold, Jennifer J, Nguyen, Vuong, Bougamha, Walid, Duran, Mónica Asencio, Squirrell, David, Mark Gillies, Arnold, Jennifer, J., Jennifer J. Arnold, Arnold, Jennifer J., Ester Carreño, Walid Bougamha, Carreño, Ester, Catherine Creuzot-Garcher, Hemal Mehta, Vuong Nguyen, Viola, Francesco, Pierre-Henry Gabrielle, Barthelmes, Daniel, Barthelmes, Daniel; https://orcid.org/, Squirrell, David; https://orcid.org/, Nguyen, Vuong; https://orcid.org/, Creuzot-Garcher, Catherine; https://orcid.org/, Gillies, Mark; https://orcid.org/, Gabrielle, Pierre-Henry; https://orcid.org/   +34 more
core   +1 more source

3D modeling of aflibercept transport in the vitreous humor [PDF]

, 2017
Aflibercept is an anti-vascular endothelial growth factor (anti-VEGF) drug used to treat several retinal diseases such as macular degeneration. It accomplishes this by binding and inhibiting VEGF, which is the growth factor that is responsible for ...
Limjoco, Matthew, Zarate, Jason, Li, Kevin   +2 more
core   +4 more sources

Intravitreal faricimab in patients with nAMD: French data from the Fight Retinal Blindness! Registry

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess real‐world outcomes of intravitreal faricimab in French patients with neovascular age‐related macular degeneration (nAMD) previously treated with vascular endothelial growth factor (VEGF) inhibitors using data from the Fight Retinal Blindness! (FRB!) Registry.
Eloi Debourdeau, Déborah Harboun, Pierre‐Henry Gabrielle, Yohei Hashimoto, Chloe Chamard, Frederic Michon, Benjamin Wolff, Héloïse Torres‐Villaros, Audrey Giocanti‐Auregan, Mark Gillies, Catherine Creuzot–Garcher, Vincent Daien   +11 more
wiley   +1 more source

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema

Therapeutic Advances in Ophthalmology
Summary What is this summary about? This is a summary of a publication about the 2-year (96-week) results from the PHOTON study, which was published in Ophthalmology . Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes.
Diana V. Do, Charles C. Wykoff, Sobha Sivaprasad, David M. Brown, David S. Boyer, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, András Seres, Sergio Leal, Robert Vitti, Karen W. Chu, Kimberly Reed, Yenchieh Cheng, Rafia Bhore, Zhanying Bai, Ursula Schmidt-Ott, Thomas Schmelter, Andrea Schulze, Zoran Hasanbasic, Peter J. Morgan-Warren, Xin Zhang, Alyson J. Berliner   +23 more
doaj   +1 more source

Five‐Year Treatment Outcomes of Macular Oedema Secondary to Central Retinal Vein Occlusion in Routine Clinical Practice: The Fight Retinal Blindness! Registry

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To report 5‐year outcomes in a cohort of patients who received anti‐VEGF therapy for macular oedema secondary to central retinal vein occlusion (CRVO) in routine clinical practice. Methods In this retrospective observational study, 593 treatment‐naïve eyes that commenced anti‐VEGF treatment between 1 January 2010, and 2019 were ...
Katrin Rudolph, Marianna Rosso, Mark Gillies, Adrian Hunt, Louise O'Toole, Alessandro Invernizzi, David Squirrell, Hemal Mehta, Richard Barry, Pierre‐Henry Gabrielle, Daniel Barthelmes   +10 more
wiley   +1 more source